论文部分内容阅读
[目的]比较胺碘酮和莫雷西嗪治疗冠心病心肌缺血患者室性心律失常的疗效。[方法]80例冠心病心肌缺血合并室性心律失常患者,均接受冠心病正规治疗,其中40例同时口服胺碘酮片(胺碘酮组),40例口服莫雷西嗪片(莫雷西嗪组),疗程4周。疗程开始及结束时均行24h动态心电图及12导联心电图检查。[结果]两组患者用药后24h室性早搏、短阵室性心动过速的发作次数均明显减少,胺碘酮组用药后与用药前比较分别为(7438±3940)个和(1924±1126)个,(10.82±4.61)次和(2.38±1.24)次;莫雷西嗪组则分别为(7122±3375)个和(3886±1687)个,(10.60±3.92)次和(4.89±2.18)次,P均﹤0.05。胺碘酮组的疗效高于莫雷西嗪组(P﹤0.01)。两组均未见严重副作用。[结论]胺碘酮对冠心病伴室性心律失常的疗效优于莫雷西嗪。
[Objective] To compare the efficacy of amiodarone and methicillin in the treatment of ventricular arrhythmia in patients with coronary heart disease. [Method] 80 cases of coronary heart disease with myocardial ischemia and ventricular arrhythmia were received formal treatment of coronary heart disease, including 40 cases of simultaneous oral amiodarone tablets (amiodarone group), 40 cases of oral Moresitir tablets (Mo Lei Xi Zu group), treatment for 4 weeks. 24 hours after the beginning and end of treatment dynamic ECG and 12-lead ECG. [Results] The incidences of ventricular premature beat and paroxysmal ventricular tachycardia were significantly decreased in both groups at 24 h after drug administration. The amiodarone group (7438 ± 3940) and (1924 ± 1126) (10.82 ± 4.61) times and (2.38 ± 1.24) times in the metoclopramide group and (7122 ± 3375) and (3886 ± 1687) days respectively in the metrescine group (10.60 ± 3.92) and (4.89 ± 2.18) ) Times, P <0.05. The efficacy of amiodarone group was higher than that of methicillin group (P <0.01). No serious side effects were seen in either group. [Conclusion] Amiodarone is superior to methicillin in treating coronary heart disease with ventricular arrhythmia.